FDA Will Publish “Critical Path” Opportunities List By Fall, Woodcock Says
Executive Summary
FDA plans to finalize its list of "Critical Path" opportunities by early fall, Acting Deputy Commissioner for Operations Janet Woodcock said
You may also be interested in...
FDA “Critical Path” Will Emphasize Clinical Trial Simulation For Drugs
FDA's "Critical Path" initiative will encourage drug manufacturers to use computer modeling to improve clinical trial design, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said
FDA “Critical Path” Will Emphasize Clinical Trial Simulation For Drugs
FDA's "Critical Path" initiative will encourage drug manufacturers to use computer modeling to improve clinical trial design, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said
FDA Seeks Comparative Trials, Public Relations Makeover For Obesity Drugs
FDA's research priorities for anti-obesity medicines include gathering data on long-term use of phentermine, particularly in comparison to newer agents, Metabolic & Endocrine Drug Products Division Director David Orloff, MD, told the FDA Science Board Advisory Committee April 22